Familial pancreatic cancer with PALB2 and NBN pathogenic variants: a case report

Background Family history is one of the risk factors for pancreatic cancer. It is suggested that patients with pancreatic cancer who have a familial history harbor germline pathogenic variants of BRCA1 and/or BRCA2 (BRCA1/2), PALB2, or ATM. Recently, some germline variants of familial pancreatic cancers (FPCs), including PALB2, have been detected. Several countries, including Japan, perform screening workups and genetic analysis for pancreatic cancers. We have been carrying out active surveillance for FPC through epidemiological surveys, imaging analyses, and genetic analysis. Case presentation Here, we present the case of a female patient harboring pathogenic variants of PALB2 and NBN, with a family history of multiple pancreatic cancer in her younger brother, her aunt, and her father. Moreover, her father harbored a PALB2 pathogenic variant and her daughter harbored the same NBN pathogenic variant. Given the PALB2 and NBN variants, we designed surveillance strategies for the pancreas, breast, and ovary. Conclusions Further studies are required to develop strategies for managing FPCs to facilitate prompt diagnosis before their progression.


Background
Pancreatic cancer is one of the most lethal malignant diseases, despite the development of medical technology, including surgical skills and anticancer drugs. Moreover, it is difficult to detect pancreatic cancer through clinical examination due to the absence of novel biomarkers. Numerous recent studies have reported that some pancreatic cancers have hereditary factors and germline variants, especially in DNA repair genes. This is similar to the mechanism of hereditary breast and ovarian cancer (HBOC) syndrome caused by the BRCA1/2 germline variant. In the National Clinical Cancer Network (NCCN) guidelines, revised in 2020, familial pancreatic cancer (FPC) was included in the HBOC syndrome because FPC harbors BRCA1/2 germline variants to some extent [1]. Furthermore, recent studies have reported that BRCA1/2 pathogenic variants potentially contribute to FPC and that the frequency of BRCA1/2, PALB2, and ATM variants in all pancreatic cancers is 7% [2][3][4].
Here, we report a pedigree with a lineage of strongly suspected FPC, resulting from PALB2 and NBN pathogenic variants. PALB2, a partner and localizer of BRCA2, is a Fanconi anemia group protein (FANCN), which permits stable intranuclear localization and accumulation of BRCA2 and can cause pancreatic, breast, and ovarian cancer [5]. To our knowledge, this is the first reported case of a Japanese pedigree harboring both PALB2 and NBN variants. Furthermore, this study describes a literature review on the latest reports and management strategies related to FPC.

Case presentation
A 49-year-old woman at first consultation presented at our hospital for surveillance of the pancreas because her father (II-3) and her younger brother (III-6) had pancreatic cancer. She had undergone surgery for subarachnoid hemorrhage at 19 years of age because of an arteriovenous malformation. Her family tree (Fig. 1) revealed that her younger brother died of pancreatic cancer at 33 years of age; he could not be treated through surgery because of his advanced stage with distant metastasis. The patient's paternal aunt (II-1) also died of pancreatic cancer at 65 years of age. Her father was also diagnosed with advanced-stage pancreatic cancer, which could not be controlled despite chemotherapy.
In the first genetic counseling session, the patient was informed that she was likely to have FPC, Lynch syndrome, or HBOC syndrome, all of which follow an autosomal dominant inheritance pattern. Therefore, germline multi-gene panel testing using ACTRisk® (ACT Genomics, Co. Ltd. Taipei, Taiwan) was performed to analyze germline variants in this case.
In the second genetic counseling session, we informed her that the blood genetic test revealed two germline variants. She harbored a heterozygous PALB2 pathogenic variant, NM_024675(PALB2): c.1675_1676inv (p.Gln559*), and a heterozygous NBN pathogenic variant, NM_ 002485(NBN): c.265C > T (p.Arg89*). These variants are predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. Therefore, we advised her to undergo surveillance for breast, ovarian, and pancreatic cancer. Her father died 9 months after her first consultation; however, he had previously provided a blood sample to our department before his death to support her future healthcare. Accordingly, genetic testing of her father's blood sample was recommended to her.
In the third genetic counseling session, we explained that her father's blood revealed the presence of the PALB2 c.1675_1676inv (p.Gln559) pathogenic variant, which was the same as hers. Furthermore, we informed her that her first-degree relatives (FDR) have a 50% chance of testing positive for these variants. Therefore, we recommended genetic counseling for her children at the next session, and she agreed.
In the fourth genetic counseling session, the patient and her three children, a 28-year-old woman, a 24-yearold man, and a 22-year-old man, presented at our outpatient department. We explained to them that their mother and her father harbored the PALB2 pathogenic variant, which was probably associated with breast, ovarian, pancreatic, and prostate cancer. Furthermore, we informed them that their mother harbored the NBN pathogenic variant, which was potentially associated with breast, ovarian, and pancreatic cancer. Upon surveillance, no issue was noted in the cases's breasts and ovaries; however, she displayed a branch duct type intraductal papillary mucinous neoplasm (BD-IPMN) in her pancreas. We suggested she continue active surveillance of her breasts, ovaries, and pancreas. Furthermore, Fig. 1 Family history of the pedigree. I-1: Dead from lung cancer at 69 years of age. I-2: Dead from endometrial cancer at 40 years of age. II-2: Dead from pancreatic cancer when she was 65 years of age. II-3: Dead from gastric cancer at 49 years of age. II-5: Diagnosed with unresectable pancreatic cancer after his son died. After the first genetic counseling, he underwent chemotherapy for cancer but died at 75 years of age. III-5: The PALB2/NBN pathogenic variants and branch-duct type IPMN. She has three children; a 28-year-old daughter (IV-3), a 24-year-old son (IV-4), and a 22-year-old son (IV-5). III-6: Diagnosed with advanced pancreatic adenocarcinoma at 32 years of age. He passed away despite undergoing chemotherapy for 10 months. IV-3: The NBN pathogenic variant her 28-year-old daughter wished to undergo genetic testing because her uncle had died from pancreatic cancer at an early age. Therefore, we performed genetic testing at a single site for the patient's daughter. Finally, the patient's daughter underwent genetic counseling and was found to harbor only the NBN c.265C > T(p.Arg89*) pathogenic variant, which was probably associated with breast, ovarian, pancreatic cancer. Thus, the daughter will be recommended to undergo surveillance for breast, ovarian, and pancreatic cancer.

Discussion and conclusions
We reported a pedigree with FPC, harboring a PALB2 pathogenic variant. Based on family history, the patient's father and younger brother and her father's sister had pancreatic cancer, whereas her mother's family did not have a cancer history. Thus, her PALB2 variant was inherited from her father, as revealed through genetic analysis. Furthermore, she had BD-IPMN, which can develop into pancreatic cancer. BD-IPMN cases are reportedly at a lower risk of pancreatic cancer than those with main-duct-type IPMN or mixed-type IPMN; however, invasive pancreatic cancer has reportedly occurred in approximately 3.8% of BD-IPMN cases after 84 months follow-up [6]. Hence, we intend to follow the present case annually using magnetic resonance imaging (MRI) or endoscopic ultrasound (EUS) imaging. Furthermore, the patient and her daughter harbored the NBN pathogenic variant, which reportedly elevates the risk of breast, ovarian, and pancreatic cancer.
A case of FPC was first reported in 1976 in a patient presenting multiple instances of pancreatic cancer in their family history [7]. The FPC registry was first developed at Johns Hopkins University in the United States in 1994. The Japanese Familial Pancreatic Cancer Registry (JFPCR) was established in 2014; it serves to recruit patients with pancreatic tumors and their first-and second-degree relatives. Furthermore, the JFPCR provides information regarding a patient's family history and lifestyle [8,9] but does not include germline variants [8,9]. Germline variants of FPC have been reported at various institutes, and the most common germline variant is the DNA repair gene family, including BRCA1/2, ATM, PALB2, CHEK2, and RAD51 [10].
The BRCA2 variant is more frequent (approximately 4-17%) among patients with FPC than is BRCA1, and the PALB2 variant has been observed in 2-3% of cases [11]. PALB2, which encodes a BRCA2-interacting protein, was first reported as a breast cancer susceptibility gene in 2007 [12]. Biallelic PALB2 variants are responsible for a subset of Fanconi anemia cases characterized by a phenotype similar to that caused by biallelic BRCA1/2 variants [13]. Most patients with FPC and HBOC syndrome harbor monoallelic PALB2 or BRCA1/ 2 variants, which follow an autosomal dominant inheritance pattern [13].
NBN, discovered as a cause of Nijmegan breakage syndrome through biallelic pathogenic variants, is a type of DNA damage response gene that is associated with severe microcephaly, infertility, and cancer risk [14]. The 95-kDa NBN protein has 754 amino acid residues and is a component of the MRN complex comprising MRE11, RAD50, and NBN. The MRN complex is one of the first players to detect double-stranded breaks and be recruited to chromatin through interactions between poly-ADP-ribose (PAR) and its first BRCT domain [15]. NBN is potentially susceptible to variation in breast and ovarian cancers [16]; however, this pathogenic variant is less known than BRCA1/2, ATM, or PALB2. Moreover, recent studies have reported that the NBN variant is associated with pancreatic cancer [17,18]. In our case, the NBN variant may have been inherited from her mother's lineage or may have originated de novo, although no studies have reported de novo NBN variants. The patient's daughter harbored the same NBN variant; hence, continued surveillance of the breast, ovary, and pancreas is needed.
One of the most important considerations from this case is determining how we should perform cancer surveillance for unaffected family members who harbor germline variants. HBOC is the most frequent hereditary tumor, and management guidelines have been established worldwide; however, no standardized surveillance methods are available for FPC. Furthermore, no guidelines for non-BRCA1/2 HBOC are available in Japan, despite the increasing number of non-BRCA1/2 HBOC cases. To resolve these issues, surveillance for FPC and management guidelines for HBOC and FPC should be considered as soon as possible.
According to the report from the evidence-based network for the interpretation of germline mutant alleles (ENGIMA) clinical working group, breast cancer surveillance for PALB2 is different across countries [19]. For example, the United States, France, Spain, Australia, and Germany recommend an annual mammogram and breast MRI from the age of 30 years and consider reduced risk mastectomy (RRM), whereas Belgium, the United Kingdom, and Japan have no guidelines regarding PALB2 management. The guideline regarding NBN surveillance in the United States is for individuals with the NBN variant to undergo mammograms and breast MRIs from the age of 40 years. The Japanese management of non-BRCA1/2 pathogenic variants, including PALB2, ATM, and NBN, should be concreated because non-BRCA1/2 genes are greatly associated with hereditary pancreatic cancer.
Our institute performs pancreatic cancer surveillance for cases with germline variants in accordance with the International Cancer of Pancreas Screening (CAPS) established in 2013 by Johns Hopkins University [20]. We denote the following as high-risk individuals (HRI): persons with three or more blood relatives with pancreatic cancer, those with at least two affected FDRs, patients with Peutz-Jeghers syndrome, and those who already harbor germline variants in BRCA1/2, PALB2, ATM, CDKN2A, MLH1, MSH2, MSH6, EPCAM, STK11, and TP53. We then perform abdominal MRIs for HRI and, if they have no issue in the pancreas, we recommend an annual abdominal MRI. If they have issues in the pancreas, we perform endoscopic ultrasound (EUS). This surveillance has been recommended in accordance with the NCCN guidelines 2020 Ver1 [1]. Accordingly, the patient and her daughter in this case study need to undergo breast, ovary, and pancreatic cancer surveillance, and the her two sons need to undergo genetic counseling.
In conclusion, we reported a family with hereditary pancreatic cancer harboring pathogenic variants of both PALB2 and NBN. The PALB2 pathogenic variant in our case was inherited from her father, and her NBN pathogenic variant was inherited by her daughter. This case indicated that we should share and generalize our knowledge and perform active surveillance of HRIs for pancreatic cancer. Furthermore, a prospective cohort study and registration system, including gene variants to establish national or international guidelines, is required. In conclusion, an increased number of studies on FPC would help establish management guidelines for the surveillance or screening of pancreatic cancer to detect early-stage cancer and improve prognosis.